Hormone Immunoassay Interference: A 2021 Update

다국어 초록 (Multilingual Abstract)

Immunoassays are powerful qualitative and quantitative analytical techniques. Since the first description of an immunoassay method in 1959, advances have been made in assay designs and analytical characteristics, opening the door for their widespread implementation in clinical laboratories. Clinical endocrinology is closely linked to laboratory medicine because hormone quantification is important for the diagnosis, treatment, and prognosis of endocrine disorders. Several interferences in immunoassays have been identified through the years; although some are no longer encountered in daily practice, cross-reaction, heterophile antibodies, biotin, and anti-analyte antibodies still cause problems. Newer interferences are also emerging with the development of new therapies. The interfering substance may be exogenous (e.g., a drug or substance absorbed by the patient) or endogenous (e.g., antibodies produced by the patient), and the bias caused by interference can be positive or negative. The consequences of interference can be deleterious when clinicians consider erroneous results to establish a diagnosis, leading to unnecessary explorations or inappropriate treatments. Clinical laboratories and manufacturers continue to investigate methods for the detection, elimination, and prevention of interferences. However, no system is completely devoid of such incidents. In this review, we focus on the analytical interferences encountered in daily practice and possible solutions for their detection or elimination.

참고문헌 (Reference)

• 1 Ramaeker D, "When is elevated testosterone not testosterone? When it is an immunoassay interfering antibody" 90 : 886-888, 2008
• 2 Lauro C, "What to do in the event of a suspicion of analytical interference during an immunoassay?" 78 : 70-73, 2020
• 3 Gurnell M, "What should be done when thyroid function tests do not make sense?" 74 : 673-678, 2011
• 4 Hattori N, "Variability in the detection of macro TSH in different immunoassay systems" 174 : 9-15, 2016
• 5 Lipner SR, "Update on biotin therapy in dermatology : time for a change" 19 : 1264-1265, 2020
• 6 Bizzarri C, "Unusual presentation of a Denys–Drash syndrome girl with undisclosed assumption of biotin" 2020
• 7 Valdes R, "Unexpected suppression of immunoassay results by cross-reactivity : now a demonstrated cause for concern" 48 : 405-406, 2002
• 8 Giovanella L, "Undetectable serum thyroglobulin due to negative interference of heterophile antibodies in relapsing thyroid carcinoma" 53 : 1871-1872, 2007
• 9 U.S. Food and Drug Administration, "UPDATE: the FDA warns that biotin may interfere with lab tests: FDA safety communication"
• 10 Heijboer AC, "Two cases of antiruthenium antibody interference in Modular free thyroxine assay" 46 : 263-264, 2009
• 11 Kazmierczak SC, "Transient nature of interference effects from heterophile antibodies : examples of interference with cardiac marker measurements" 38 : 33-39, 2000
• 12 Oei AL, "Transient human anti-mouse antibodies(HAMA)interference in CA 125 measurements during monitoring of ovarian cancer patients treated with murine monoclonal antibody" 109 : 199-202, 2008
• 13 Shimon I, "Transient elevation of triiodothyronine caused by triiodothyronine autoantibody associated with acute Epstein-Barr-virus infection" 13 : 211-215, 2003
• 14 Mi-Na Lee ; 이수연 ; 허규연 ; 박형두, "Thyroxine (T4) Autoantibody Interference of Free T4 Concentration Measurement in a Patient With Hashimoto’s Thyroiditis" 대한진단검사의학회 37 (37): 169-171, 2017
• 15 Giovanella L, "Thyroglobulin measurement by highly sensitive assays : focus on laboratory challenges" 53 : 1301-1314, 2015
• 16 Goldschmidt CH, "The rise and fall of high-dose biotin to treat progressive multiple sclerosis" 17 : 968-970, 2020
• 17 Ward G, "The investigation of interferences in immunoassay" 50 : 1306-1311, 2017
• 18 Ismail AA, "The insulin autoimmune syndrome (IAS) as a cause of hypoglycaemia: an update on the pathophysiology, biochemical investigations and diagnosis" 54 : 1715-1724, 2016
• 19 Soleymani T, "The infatuation with biotin supplementation: is there truth behind its rising popularity? A Comparative analysis of clinical efficacy versus social popularity" 16 : 496-500, 2017
• 20 Campi I, "The differential diagnosis of discrepant thyroid function tests: insistent pitfalls and updated flow-chart based on a long-standing experience" 11 : 432-, 2020
• 21 Taieb J, "Testosterone measured by 10 immunoassays and by isotope-dilution gas chromatography-mass spectrometry in sera from 116 men, women, and children" 49 : 1381-1395, 2003
• 22 Ellis MJ, "Techniques for identifying heterophile antibody interference are assay specific : study of seven analytes on two automated immunoassay analyzers" 51 : 639-641, 2005
• 23 Jonklaas J, "TSH-free thyroxine discordance in an athyreotic patient during ipiluminab and nivoluminab therapy" 2 : e296-e301, 2016
• 24 Stieglitz HM, "Suspected testosterone-producing tumor in a patient taking biotin supplements" 2 : 563-569, 2018
• 25 Gifford JL, "Strategies for mitigating risk posed by biotin interference on clinical immunoassays" 65 : 61-63, 2019
• 26 Honour JW, "Steroid assays in paediatric endocrinology" 2 : 1-16, 2010
• 27 Ross HA, "Spuriously high free thyroxine values in familial dysalbuminemic hyperthyroxinemia" 57 : 524-525, 2011
• 28 Sofronescu AG, "Spurious testosterone laboratory results in a patient taking synthetic alkaline phosphatase(asfotase alfa)" 58 : 118-121, 2018
• 29 Holm BE, "Species cross-reactivity of rheumatoid factors and implications for immunoassays" 75 : 51-63, 2015
• 30 García-González E, "Serum sample containing endogenous antibodies interfering with multiple hormone immunoassays. Laboratory strategies to detect interference" 4 : 1-10, 2015
• 31 Overgaard M, "Serum prolactin revisited : parametric reference intervals and cross platform evaluation of polyethylene glycol precipitation-based methods for discrimination between hyperprolactinemia and macroprolactinemia" 55 : 1744-1753, 2017
• 32 Hawley JM, "Serum cortisol : an up-to-date assessment of routine assay performance" 62 : 1220-1229, 2016
• 33 Moerman A, "Sense and nonsense concerning biotin interference in laboratory tests" 1-7, 2020
• 34 Cree BAC, "Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial" 19 : 988-997, 2020
• 35 Woeber KA, "Recurrent pituitary macroadenoma with increased plasma ACTH precursors that cross-react in a commonly used ACTH immunoassay" 20 : 94-96, 2014
• 36 Nahoul K, "Radioimmunoassay of plasma progesterone after oral administration of micronized progesterone" 26 : 241-249, 1987
• 37 Monaghan PJ, "Proopiomelanocortin interference in the measurement of adrenocorticotrophic hormone: a United Kingdom National External Quality Assessment Service study" 85 : 569-574, 2016
• 38 Faix JD, "Principles and pitfalls of free hormone measurements" 27 : 631-645, 2013
• 39 Koshida S, "Prevalence of human anti-mouse antibodies(HAMAs)in routine examinations" 411 : 391-394, 2010
• 40 DeCosimo DR, "Prevalence of familial dysalbuminemic hyperthyroxinemia in Hispanics" 107 : 780-781, 1987
• 41 Ijpelaar A, "Prevalence of detectable biotin in the Netherlands in relation to risk on immunoassay interference" 83 : 78-80, 2020
• 42 Katzman BM, "Prevalence of biotin supplement usage in outpatients and plasma biotin concentrations in patients presenting to the emergency department" 60 : 11-16, 2018
• 43 Whittle E, "Pre-analytical mysteries: A case of severe hypervitaminosis D and mild hypercalcaemia" 31 : 011001-, 2021
• 44 Rosner W, "Position statement: utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement" 92 : 405-413, 2007
• 45 Grimsey P, "Population pharmacokinetics of exogenous biotin and the relationship between biotin serum levels and in vitro immunoassay interference" 2 : 247-256, 2017
• 46 Fahie-Wilson M, "Polyethylene glycol precipitation : proceed with care" 45 : 233-235, 2008
• 47 Lopez AG, "Pharmacological and analytical interference in hormone assays for diagnosis of adrenal incidentaloma" 80 : 250-258, 2019
• 48 Peyro Saint Paul L, "Pharmacokinetics and pharmacodynamics of MD1003(high-dose biotin)in the treatment of progressive multiple sclerosis" 12 : 327-344, 2016
• 49 Schiettecatte J, "Performance evaluation of an automated electrochemiluminescent calcitonin(CT)immunoassay in diagnosis of medullary thyroid carcinoma" 49 : 929-931, 2016
• 50 Paisley AN, "Pegvisomant interference in GH assays results in underestimation of GH levels" 156 : 315-319, 2007
• 51 Long N, "PURLS : It’s time to reconsider early-morning testosterone tests" 64 : 418-419, 2015
• 52 Laudes M, "PTH immunoassay interference due to human anti-mouse antibodies in a subject with obesity with normal parathyroid function" 104 : 5840-5842, 2019
• 53 Pharmacovigilance Risk Assessment Committee, "PRAC recommendations on signals" European Medicines Agency
• 54 Ismail AA, "On the diagnosis of subclinical hypothyroidism" 57 : 1000-1001, 2007
• 55 Ismail AA, "On detecting interference from endogenous antibodies in immunoassays by doubling dilutions test" 45 : 851-854, 2007
• 56 Owen LJ, "Oestradiol measurement during fulvestrant treatment for breast cancer" 120 : 404-406, 2019
• 57 Barth JH, "Observational studies on macroprolactin in a routine clinical laboratory" 56 : 1259-1262, 2018
• 58 Makela SK, "Nonspecificity of a direct 17 alpha-hydroxyprogesterone radioimmunoassay kit when used with samples from neonates" 34 : 2070-2075, 1988
• 59 Ando T, "Non-specific activities against ruthenium crosslinker as a new cause of assay interference in an electrochemilluminescent immunoassay" 46 : 1225-1229, 2007
• 60 Luzzi VI, "Negative thyrotropin assay interference associated with an IgGkappa paraprotein" 49 : 709-710, 2003
• 61 Vogeser M, "Multicenter performance evaluation of a second generation cortisol assay" 55 : 826-835, 2017
• 62 Barbesino G, "Misdiagnosis of Graves’ disease with apparent severe hyperthyroidism in a patient taking biotin megadoses" 26 : 860-863, 2016
• 63 Giovanella L, "Measuring procalcitonin to overcome heterophilic-antibody-induced spurious hypercalcitoninemia" 56 : e191-e193, 2018
• 64 Benton SC, "Measured dehydroepiandrosterone sulfate positively influences testosterone measurement in unextracted female serum : comparison of 2 immunoassays with testosterone measured by LC-MS" 57 : 1074-1075, 2011
• 65 Richa V, "Macroprolactin; a frequent cause of misdiagnosed hyperprolactinemia in clinical practice" 11 : 161-167, 2010
• 66 Loh TP, "Macro-thyrotropin : a case report and review of literature" 97 : 1823-1828, 2012
• 67 Halsall DJ, "Macro thyrotropin-IgG complex causes factitious increases in thyroid-stimulating hormone screening tests in a neonate and mother" 52 : 1968-1969, 2006
• 68 Raverot V, "Letter to the editor: A case of laboratory-generated “thyroid dysfunction”" 80 : 140-141, 2019
• 69 Altawallbeh G, "Letter to the Editor: assay-specific spurious ACTH results lead to misdiagnosis, unnecessary testing, and surgical misadventure–A case series" 4 : bvz011-, 2019
• 70 Faye SA, "Investigation and resolution of the effect of an interfering factor in the Beckman Coulter anti-Müllerian hormone(AMH)Gen II ELISA assay" 29 : 331-, 2014
• 71 Visser WE, "Interpretation of thyroid function tests during pregnancy" 34 : 101431-, 2020
• 72 Haddad RA, "Interpretation of common endocrine laboratory tests: technical pitfalls, their mechanisms and practical considerations" 5 : 12-, 2019
• 73 "Interlaboratory survey of methods for measuring human anti-mouse antibodies. HAMA Survey Group" 38 : 172-173, 1992
• 74 Favresse J, "Interferences with thyroid function immunoassays : clinical implications and detection algorithm" 39 : 830-850, 2018
• 75 Tate J, "Interferences in immunoassay" 25 : 105-120, 2004
• 76 Klee GG, "Interferences in hormone immunoassays" 24 : 1-18, 2004
• 77 Verougstraete N, "Interference of anti-streptavidin antibodies in immunoassays : A very rare phenomenon or a more common finding?" 58 : 1673-1680, 2020
• 78 Imperiali M, "Interference in thyroid-stimulating hormone determination" 40 : 756-758, 2010
• 79 Zaninotto M, "Interference in thyroid hormones with Roche immunoassays : an unfinished story" 52 : e269-e270, 2014
• 80 Selby C, "Interference in immunoassay" 36 : 704-721, 1999
• 81 Ismail AA, "Interference from endogenous antibodies in automated immunoassays : what laboratorians need to know" 62 : 673-678, 2009
• 82 Rulander NJ, "Interference from anti-streptavidin antibody" 137 : 1141-1146, 2013
• 83 Henry JG, "Interference by biotin therapy on measurement of TSH and FT4 by enzyme immunoassay on Boehringer Mannheim ES700 analyser" 33 : 162-163, 1996
• 84 Buijs MM, "Interference by antiruthenium antibodies in the Roche thyroid-stimulating hormone assay" 48 : 276-281, 2011
• 85 Pappa T, "Inherited defects of thyroxine-binding proteins" 29 : 735-747, 2015
• 86 Zouwail SA, "Influence of thyroid hormone autoantibodies on 7 thyroid hormone assays" 54 : 927-928, 2008
• 87 Thomas CM, "Inaccurate measurement of 17 beta-estradiol in serum of female volunteers after oral administration of milligram amounts of micronized 17 beta-estradiol" 39 : 2341-2342, 1993
• 88 Webster R, "Immunoglobulin interference in serum follicle-stimulating hormone assays : autoimmune and heterophilic antibody interference" 47 : 386-389, 2010
• 89 Hattori N, "Immunoglobulin G subclasses and prolactin(PRL)isoforms in macroprolactinemia due to anti-PRL autoantibodies" 90 : 3036-3044, 2005
• 90 Darwish IA, "Immunoassay methods and their applications in pharmaceutical analysis : basic methodology and recent advances" 2 : 217-235, 2006
• 91 Evans N, "Immunoassay interference secondary to therapeutic high-dose biotin : A paediatric case report" 54 : 572-575, 2018
• 92 Choy KW, "Immunoassay interference complicating management of Cushing’s disease : the onus is on the clinician and the laboratory" 54 : 183-184, 2017
• 93 Lefèvre CR, "Immunoassay disruption by high-dose biotin therapy : fair warning for neonatal care physicians" 112 : 8-9, 2020
• 94 Ismail AA, "Identifying and reducing potentially wrong immunoassay results even when plausible and"not-unreasonable"" 66 : 241-294, 2014
• 95 Wong T, "Identification of the steroids in neonatal plasma that interfere with 17 alpha-hydroxyprogesterone radioimmunoassays" 38 : 1830-1837, 1992
• 96 Aliberti L, "Hypeprolactinemia : still an insidious diagnosis" 72 : 928-931, 2021
• 97 Kricka LJ, "Human anti-animal antibody interferences in immunological assays" 45 : 942-956, 1999
• 98 Spencer C, "How sensitive (second-generation) thyroglobulin measurement is changing paradigms for monitoring patients with differentiated thyroid cancer, in the absence or presence of thyroglobulin autoantibodies" 21 : 394-404, 2014
• 99 Piketty ML, "High-dose biotin therapy leading to false biochemical endocrine profiles : validation of a simple method to overcome biotin interference" 55 : 817-825, 2017
• 100 Motte J, "High-dose biotin in multiple sclerosis : the end of the road" 19 : 965-966, 2020
• 101 Lamy PJ, "High fasting serum insulin level due to autoantibody interference in insulin immunoassay discloses autoimmune insulin syndrome: a case report" 74 : 490-494, 2016
• 102 Wolf B, "High doses of biotin can interfere with immunoassays that use biotin-strept(avidin)technologies : implications for individuals with biotin-responsive inherited metabolic disorders" 127 : 321-324, 2019
• 103 Cheng X, "Heterophilic antibody interference with TSH measurement on different immunoassay platforms" 512 : 63-65, 2021
• 104 Bolstad N, "Heterophilic antibody interference in immunometric assays" 27 : 647-661, 2013
• 105 Mongolu S, "Heterophilic antibody interference affecting multiple hormone assays : is it due to rheumatoid factor?" 76 : 240-242, 2016
• 106 Brugts MP, "Heterophilic antibodies may be a cause of falsely low total IGF1 levels" 161 : 561-565, 2009
• 107 Berglund Land Holmberg NG, "Heterophilic antibodies against rabbit serum causing falsely elevated gonadotropin levels" 68 : 377-378, 1989
• 108 Boscato LM, "Heterophilic antibodies : a problem for all immunoassays" 34 : 27-33, 1988
• 109 Kim D, "Heterophile antibody interference associated with natural killer cell therapy" 67 : 1187-1192, 2020
• 110 Cormano J, "Gestational trophoblastic disease diagnosis delayed by the hook effect" 126 : 811-814, 2015
• 111 Trambas CM, "Further assessment of the prevalence of biotin supplementation and its impact on risk" 65 : 64-65, 2019
• 112 Castinetti F, "French endocrine society guidance on endocrine side effects of immunotherapy" 26 : G1-G18, 2019
• 113 Dieu X, "Familial dysalbuminemic hyperthyroxinemia : an underdiagnosed entity" 9 : 2105-, 2020
• 114 Cartwright D, "Familial dysalbuminemic hyperthyroxinemia : A persistent diagnostic challenge" 55 : 1044-1046, 2009
• 115 Khoo S, "Familial dysalbuminaemic hyperthyroxinaemia interferes with current free thyroid hormone immunoassay methods" 182 : 533-538, 2020
• 116 Drees JC, "Falsely undetectable TSH in a cohort of South Asian euthyroid patients" 99 : 1171-1179, 2014
• 117 Santhana Krishnan SG, "Falsely raised TSH levels due to human anti-mouse antibody interfering with thyrotropin assay" 82 : e27-, 2006
• 118 Hager HB, "Falsely markedly elevated 25-hydroxyvitamin D in patients with monoclonal gammopathies" 59 : 663-669, 2021
• 119 Ohba K, "Falsely elevated thyroid hormone levels caused by anti-ruthenium interference in the Elecsys assay resembling the syndrome of inappropriate secretion of thyrotropin" 59 : 663-667, 2012
• 120 Mandic S, "Falsely elevated serum oestradiol due to exemestane therapy" 54 : 402-405, 2017
• 121 Hillebrand JJ, "Falsely decreased thyroglobulin levels in a patient with differentiated thyroid carcinoma" 509 : 217-219, 2020
• 122 Astarita G, "False positive in the measurement of thyroglobulin induced by rheumatoid factor" 447 : 43-46, 2015
• 123 Cavalier E, "False positive PTH results : an easy strategy to test and detect analytical interferences in routine practice" 387 : 150-152, 2008
• 124 Piketty ML, "False biochemical diagnosis of hyperthyroidism in streptavidin-biotin-based immunoassays : the problem of biotin intake and related interferences" 55 : 780-788, 2017
• 125 Koehler VF, "Fake news? Biotin interference in thyroid immunoassays" 484 : 320-322, 2018
• 126 Giurgea I, "Factitious hyperinsulinism leading to pancreatectomy : severe forms of Munchausen syndrome by proxy" 116 : e145-e148, 2005
• 127 Elston MS, "Factitious Graves’ disease due to biotin immunoassay interference-A case and review of the literature" 101 : 3251-3255, 2016
• 128 Piketty ML, "FGF23 measurement in burosumab-treated patients : an emerging treatment may induce a new analytical interference" 58 : e267-e269, 2020
• 129 Sturgeon CM, "External quality assessment of hormone determinations" 27 : 803-822, 2013
• 130 Lahlou N, "Expert opinions on endocrine toxicity induced by new anticancer therapies: precautions to be taken in performing and interpreting hormonal assays under immunotherapy" 79 : 550-554, 2018
• 131 van der Watt G, "Euthyroid patient with elevated serum free thyroxine" 54 : 1239-1241, 2008
• 132 Bayart JL, "Erroneous thyroid and steroid hormones profile due to anti-streptavidin antibodies" 57 : e255-e258, 2019
• 133 Emerson JF, "Endogenous antibody interferences in immunoassays" 44 : 69-73, 2013
• 134 Dahll LK, "Endogenous anti-streptavidin antibodies causing erroneous laboratory results more common than anticipated" 81 : 92-103, 2021
• 135 Rix M, "Elevated thyroid-stimulating hormone level in a euthyroid neonate caused by macro thyrotropin-IgG complex" 100 : e135-e137, 2011
• 136 Cole LA, "Easy fix for clinical laboratories for the false-positive defect with the Abbott AxSym total β-hCG test" 37 : 344-349, 2004
• 137 Srichomkwun P, "Diagnostic dilemma in discordant thyroid function tests due to thyroid hormone autoantibodies" 3 : e22-e25, 2017
• 138 Lu RM, "Development of therapeutic antibodies for the treatment of diseases" 27 : 1-, 2020
• 139 Fahie-Wilson M, "Determination of prolactin : the macroprolactin problem" 27 : 725-742, 2013
• 140 Maharjan AS, "Detection and characterization of estradiol(E2)and unconjugated estriol(uE3)immunoassay interference due to anti-bovine alkaline phosphatase(ALP)antibodies" 17 : e00131-, 2019
• 141 Dias ML, "Detecting and solving the interference of pregnancy serum, in a GH immunometric assay" 23 : 13-18, 2013
• 142 Trambas C, "Depletion of biotin using streptavidin-coated microparticles : a validated solution to the problem of biotin interference in streptavidin-biotin immunoassays" 55 : 216-226, 2018
• 143 Feldt MM, "Delayed diagnosis of congenital hypothyroidism in a child with trisomy 21 and biotinidase deficiency and successful use of levothyroxine sodium oral solution" 2020 : 8883969-, 2020
• 144 Warner MH, "Dehydroepiandrosterone sulphate interferes with the Abbott Architect direct immunoassay for testosterone" 43 : 196-199, 2006
• 145 Krasowski MD, "Cross-reactivity of steroid hormone immunoassays : clinical significance and two-dimensional molecular similarity prediction" 14 : 33-, 2014
• 146 Dayaldasani A, "Cross-reactivity of insulin analogues with three insulin assays" 52 : 312-318, 2015
• 147 Colucci R, "Correlation of serum thyroid hormones autoantibodies with self-reported exposure to thyroid disruptors in a group of nonsegmental vitiligo patients" 69 : 181-190, 2015
• 148 Köhler G, "Continuous cultures of fused cells secreting antibody of predefined specificity" 256 : 495-497, 1975
• 149 Parfitt C, "Commercial insulin immunoassays fail to detect commonly prescribed insulin analogues" 48 : 1354-1357, 2015
• 150 Kragh-Hansen U, "Clinical, genetic, and protein structural aspects of familial dysalbuminemic hyperthyroxinemia and hypertriiodothyroninemia" 8 : 297-, 2017
• 151 Piketty ML, "Clinical comparison of three labeled-antibody immunoassays of free triiodothyronine" 42 : 933-941, 1996
• 152 U.S. Food and Drug Administration medical devices databases, "Class 2 device recall ST AIAPACK ACTH (ACTH)"
• 153 Gnocchi D, "Circadian rhythms and hormonal homeostasis: pathophysiological implications" 6 : 10-, 2017
• 154 Ranaivosoa MK, "Chronic kidney failure and biotin: A combination inducing unusual results in thyroid and parathyroid investigations, report of 2 cases" 13 : 553-558, 2017
• 155 Bergman D, "Characterization of canine anti-mouse antibodies highlights that multiple strategies are needed to combat immunoassay interference" 9 : 14521-, 2019
• 156 Caruso B, "Causes of preanalytical interferences on laboratory immunoassays–A critical review" 31 : 70-84, 2020
• 157 Kummer S, "Biotin treatment mimicking Graves’ disease" 375 : 704-706, 2016
• 158 Carter GD, "Biotin supplementation causes erroneous elevations of results in some commercial serum 25-hydroxyvitamin D(25OHD)assays" 200 : 105639-, 2020
• 159 Plasse RA, "Biotin supplement interference with immunoassays for parathyroid hormone and 25-hydroxyvitamin D in a patient with metabolic bone disease on maintenance hemodialysis" 13 : 710-712, 2020
• 160 Avery G, "Biotin interference in immunoassay : a review for the laboratory scientist" 56 : 424-430, 2019
• 161 Mzougui S, "Biotin interference : evaluation of a new generation of electrochemiluminescent immunoassays for high-sensitive troponin T and thyroid-stimulating hormone testing" 58 : 2037-2045, 2020
• 162 Sanders A, "Biotin immunoassay interference : a UK-based prevalence study" 58 : 66-69, 2021
• 163 Bülow Pedersen I, "Biochemical hyperthyroidism in a newborn baby caused by assay interaction from biotin intake" 5 : 212-215, 2016
• 164 Bowen R, "Best practices in mitigating the risk of biotin interference with laboratory testing" 74 : 1-11, 2019
• 165 Beato-Víbora PI, "Avoiding misdiagnosis due to antibody interference with serum free thyroxin" 15 : e37792-, 2016
• 166 Manolopoulou J, "Automated 22-kD growth hormone-specific assay without interference from Pegvisomant" 58 : 1446-1456, 2012
• 167 Lupsa BC, "Autoimmune forms of hypoglycemia" 88 : 141-153, 2009
• 168 Keevil BG, "Assessment of free testosterone concentration" 190 : 207-211, 2019
• 169 Turner KA, "Assessment of complement interference in anti-Müllerian hormone immunoassays" 58 : e8-e10, 2020
• 170 John JJ, "Assessment of biotin supplementation among patients in an outpatient dermatology clinic" 81 : 620-621, 2019
• 171 Zhang Y, "Assessment of biotin interference in thyroid function tests" 99 : e19232-, 2020
• 172 Ong MW, "Artefactual 25-OH vitamin D concentration in multiple myeloma" 54 : 716-720, 2017
• 173 Pillay Tahir S. ; Muyldermans Serge, "Application of Single-Domain Antibodies (“Nanobodies”) to Laboratory Diagnosis" 대한진단검사의학회 41 (41): 549-558, 2021
• 174 Lam L, "Apparent hyperthyroidism caused by biotin-like interference from IgM anti-streptavidin antibodies" 28 : 1063-1067, 2018
• 175 Papo T, "Antithyroid hormone antibodies induced by interferon-alpha" 75 : 1484-1486, 1992
• 176 Massart C, "Anti-thyroxine and anti-triiodothyronine antibody interferences in one-step free triiodothyronine and free thyroxine immunoassays" 401 : 175-176, 2009
• 177 Peltier L, "Anti-streptavidin interferences in Roche thyroid immunoassays : a case report" 54 : e11-e14, 2016
• 178 Favresse J, "Anti-streptavidin antibodies mimicking heterophilic antibodies in thyroid function tests" 56 : e160-e163, 2018
• 179 Berth M, "Anti-streptavidin IgG antibody interference in anti-cyclic citrullinated peptide(CCP)IgG antibody assays is a rare but important cause of false-positive anti-CCP results" 56 : 1263-1268, 2018
• 180 Fruzzetti F, "Anti-goat antibodies as a rare cause of high gonadotropin levels during menopausal transition" 36 : 938-940, 2020
• 181 Sturgeon CM, "Analytical error and interference in immunoassay : minimizing risk" 48 : 418-432, 2011
• 182 Covinsky M, "An IgM lambda antibody to Escherichia coli produces false-positive results in multiple immunometric assays" 46 : 1157-1161, 2000
• 183 Trambas C, "Accurate results in the clinical laboratory" Elsevier 83-97, 2019
• 184 Groenestege WM, "Accuracy of first and second generation testosterone assays and improvement through sample extraction" 58 : 1154-1156, 2012
• 185 Ohba K, "Abnormal thyroid hormone response to TRH in a case of macro-TSH and the cut-offvalue for screening cases of inappropriate TSH elevation" 67 : 125-130, 2020
• 186 Biscolla RPM, "A single 10 mg oral dose of biotin interferes with thyroid function tests" 27 : 1099-1100, 2017
• 187 Lam L, "A simple method to detect biotin interference on immunoassays" 55 : e104-e106, 2017
• 188 Wu AH, "A selected history and future of immunoassay development and applications in clinical chemistry" 369 : 119-124, 2006
• 189 Hattori N, "A possible cause of the variable detectability of macroprolactin by different immunoassay systems" 54 : 603-608, 2016
• 190 Saleem M, "A patient with pseudo-Addison’s disease and falsely elevated thyroxine due to interference in serum cortisol and free thyroxine immunoassays by two different mechanisms" 46 : 172-175, 2009
• 191 RaffH, "A new immunoradiometric assay for corticotropin evaluated in normal subjects and patients with Cushing’s syndrome" 35 : 596-600, 1989
• 192 Lim YY, "A diagnostic curiosity of isolated androstenedione elevation due to autoantibodies against horseradish peroxidase label of the immunoassay" 476 : 103-106, 2018
• 193 Gulbahar O, "A case with immunoassay interferences in the measurement of multiple hormones" 100 : 2147-2153, 2015
• 194 Meany DL, "A case of renal osteodystrophy with unexpected serum intact parathyroid hormone concentrations" 55 : 1737-1739, 2009
• 195 Haugen BR, "2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer : the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer" 26 : 1-133, 2016
• 196 Frieze TW, ""Hook effect"in prolactinomas : case report and review of literature" 8 : 296-303, 2002